The PI3K-AKT pathway, as a prominent alternative pathway, was found to be upregulated in 22% of disease-progressive melanomas, eliciting tumor escape from BRAFi and MEKi therapies (Shi et al, 2014b). This evidence concerns the gene AKT1 and melanoma.